First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Henlius Latvia China

View original content:https://www.prnewswire.co.uk/news-releases/first-patient-dosed-for-mrct-phase-3-study-on-first-line-ls-sclc-of-henlius-anti-pd-1-mab-serplulimab-in-europe-301967353.html